Business
Knight Therapeutics Reports First Quarter 2026 Results
Increased 2026 revenue guidance from $510 million to $525 million  Achieved record-high qu...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"Knight Therapeutics Reports First Quarter 2026 Results\nIncreased 2026 revenue guidance from $510 million to $525 million Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception MONTREAL, May 07, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (\"Knight\" or “the Company”), a pan-American (ex-US) pharmaceutical company, today reported financial results for its first quarter ended March 31, 2026. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1-26 Highlights Financial Results - IFRS Revenues were $148,439, an increase of $60,363 or 69% over the same period in prior year. The increase was primarily driven by the incremental revenues from the Paladin and Sumitomo portfolios, the growth of our promoted products, and the purchasing patterns of certain products including Ambisome® deliveries to the MOH.Gross margin was $69,109 or 47% of revenues compared to $34,866 or 40% of revenues in the same period in prior year. The increase in gross margin % was driven by both a higher contribution of the Canadian business in Q1-26 compared to Q1-25 and the lower impact of hyperinflation2, partly offset by product mix including a higher proportion of Ambisome® deliveries to the MOH.Operating income was $10,578 compared to an operating loss of $5,537 in the same period in prior year.Net income was $13,169, compared to $2,185 in the same period in prior year.Net income per share was $0.13, compared to $0.02 in the same period in prior year.Generated cash inflow from operations of $40,694, and ended Q1-26 with over $125,000 in cash, cash equivalents and marketable securities. Financial Results - Non-GAAP Adjusted Revenues1 were $147,594, an increase of $59,615 or 68% over the same period in prior year, or $55,395 or 60% on a constant currency1 basis, primarily driven by the incremental revenues from the Paladin and Sumitomo portfolios, the growth of our promoted products, and the purchasing patterns of certain products including Ambisome® deliveries to the MOH.Adjusted Gross Margin1 was $70,648 or 48% of Adjusted Revenues1 compared to $40,934 or 47% of Adjusted Revenues1 in the same period in prior year.. The increase in the Adjusted Gross Margin1 % was driven by a hi...